GlassScriptPhysician profile
Gerald M Sacks
NPI 1205906781
$388,543.06
in general payments reported to CMS, 2019-2025
45 companies · $3,381 in 2025
The $3,381 reported for 2025 was more than what 90% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181K · 2020: $35K · 2021: $117K · 2022: $33K · 2023: $15K · 2024: $3,572 · 2025: $3,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $6,707 · Consulting Fee: $4,650 · Travel and Lodging: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,525.00 |
| Food and Beverage | $6,707.14 |
| Consulting Fee | $4,650.00 |
| Travel and Lodging | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148,661.50 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $101,696.14 | 2019-2025 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $69,667.29 | 2020-2021 | |
| Mdd US Operations, LLC | $16,122.94 | 2019-2020 | |
| West Therapeutics Development, LLC | $15,401.82 | 2019-2021 | |
| Ibsa Pharma INC. | $10,544.79 | 2020-2025 | Licart, Tirosint, Tirosint |
| Biohaven Pharmaceutical Holding Company LTD. | $10,377.38 | 2022 | |
| Amgen INC. | $3,474.53 | 2019-2025 | Evenity, Prolia |
| Becton, Dickinson and Company | $1,300.00 | 2025 | |
| Pfizer INC. | $1,190.45 | 2019-2025 | |
| Abbvie INC. | $1,116.33 | 2021-2025 | |
| Lilly USA, LLC | $987.47 | 2020-2025 | Emgality, Reyvow |
| Horizon Therapeutics Plc | $847.77 | 2019-2022 | |
| Axsome Therapeutics, INC. | $816.45 | 2024-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $745.60 | 2019-2023 | Belbuca |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Sacks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.